F de la Cruz V, Alonso RD, Urbano IA

Language: Spanish
References: 15
Page: 101-104
PDF size: 54.73 Kb.

ABSTRACT

Immune thrombocytopenic purpura (ITP) is one of the most frequent autoimmune disorders. In adults the clinical picture of the disease is insidious with frequent relapses and refractoriness to the current treatments, evolving in many cases to a chronic ITP. The main pathogenetic finding in this disease is the presence of antiplatelet autoantibodies, causing both platelet destruction and a suboptimal platelet production in bone marrow. The high incidence of patients non-responders to first line treatments, led to the development of new drugs for this disease. Recently, second generation thrombopoitein molecules, like AMG 531 (romiplostim), have been developed and have demonstrated to be both effective and safe, without generating antibodies against human endogenous thrombopoitein.

REFERENCES

1. McMillan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1981;304:1135-1147.

2. Chong BH, Ho S-J. Autoimmune thrombocytopenia. J Thromb Haemost 2005;3:1763-1772.

3. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Thromb Haemost 2008;99:4-13.

4. Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425-442.

5. Houwerzijl JJ, Blom NR, van der Want JJ, Esselink MT, Koornstra JJ, Smit JW, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004;103:500-506.

6. Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 2005;90:72-77.

7. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:3457-3469.

8. Kuter DJ. New thrombopoietic growth factors. Blood 2007;109:4607-4616.

9. Bussel JB, Kuter DJ, Phil D, George JN, McMillan R, Aledor LM. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-1681.

10. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76(6):628-638.

11. Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T, et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol 2007;47(12):1489-1497.

12. Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006;135:547-553.

13. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371(9610):395-403.

14. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113(10):2161-2171.

15. Kuter DJ, Bussel JB, Newland A, Wolf JTM, Guthrie T, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenic purpura (ITP): 3-year update from an open-label extension study. Blood (ASH Annual Meeting Abstracts) 2008 112: Abstract 402 y presentación oral.